Schrodinger SDGR shares are trading lower on Tuesday after Morgan Stanley maintained its Equal-Weight rating on the stock and lowered its price target from $93 to $90 per share.
Schrodinger is a healthcare-based software company. Its operating segments are Software and Drug discovery. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Schrodinger shares traded down 5.90% to $58.58 on Tuesday. The stock has a 52-week high of $99.50 and a 52-week low of $25.50.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.